EA201992667A1 - Новые пептидные линкеры и конъюгаты на основе криптофицина, их получение и их терапевтическое применение - Google Patents

Новые пептидные линкеры и конъюгаты на основе криптофицина, их получение и их терапевтическое применение

Info

Publication number
EA201992667A1
EA201992667A1 EA201992667A EA201992667A EA201992667A1 EA 201992667 A1 EA201992667 A1 EA 201992667A1 EA 201992667 A EA201992667 A EA 201992667A EA 201992667 A EA201992667 A EA 201992667A EA 201992667 A1 EA201992667 A1 EA 201992667A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cryptophycin
therapeutic use
production
present
conjugates based
Prior art date
Application number
EA201992667A
Other languages
English (en)
Inventor
Эрве Бушар
Мари-Присцилл Брэн
Филипп Юбер
Original Assignee
Санофи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Санофи filed Critical Санофи
Publication of EA201992667A1 publication Critical patent/EA201992667A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid

Abstract

Настоящее изобретение относится к соединениям формулы (I)где RCG1 представляет собой реакционноспособную химическую группу, которая является реакционноспособной в отношении химической группы, присутствующей на полипептиде, таком как антитело; P представляет собой H, OH или активированный O; и L представляет собой конкретный линкер. Настоящее изобретение также относится к полезным нагрузкам с криптофицином, а также к конъюгатам на основе криптофицина, к композициям, содержащим их, и к их терапевтическому применению, особенно в качестве противораковых средств. Настоящее изобретение также относится к способу получения таких конъюгатов.
EA201992667A 2017-05-10 2018-05-09 Новые пептидные линкеры и конъюгаты на основе криптофицина, их получение и их терапевтическое применение EA201992667A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17305531 2017-05-10
PCT/EP2018/061989 WO2018206635A1 (en) 2017-05-10 2018-05-09 Peptidic linkers and cryptophycin conjugates, useful in therapy, and their preparation

Publications (1)

Publication Number Publication Date
EA201992667A1 true EA201992667A1 (ru) 2020-03-10

Family

ID=58873750

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201992667A EA201992667A1 (ru) 2017-05-10 2018-05-09 Новые пептидные линкеры и конъюгаты на основе криптофицина, их получение и их терапевтическое применение

Country Status (20)

Country Link
US (4) US20180369401A1 (ru)
EP (1) EP3621658A1 (ru)
JP (2) JP2020519610A (ru)
KR (1) KR20200005580A (ru)
CN (1) CN110831633A (ru)
AR (1) AR111781A1 (ru)
AU (2) AU2018265333C1 (ru)
BR (1) BR112019023336A2 (ru)
CA (1) CA3062977A1 (ru)
CO (1) CO2019012108A2 (ru)
EA (1) EA201992667A1 (ru)
EC (1) ECSP19078277A (ru)
IL (1) IL270507B2 (ru)
MA (1) MA50764A (ru)
MX (1) MX2019013421A (ru)
PH (1) PH12019550230A1 (ru)
TN (1) TN2019000303A1 (ru)
TW (1) TWI778059B (ru)
UY (1) UY37728A (ru)
WO (1) WO2018206635A1 (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
CN111154133B (zh) * 2020-01-03 2022-07-12 万华化学集团股份有限公司 一种环氧树脂发泡剂，环氧树脂组合物及环氧发泡材料的制备方法和用途
CN114053426A (zh) * 2020-07-30 2022-02-18 成都科岭源医药技术有限公司 一种双药链接组装单元及双药靶向接头-药物偶联物
CN115105607A (zh) * 2021-03-22 2022-09-27 成都科岭源医药技术有限公司 一种用于adc的双药-接头的制备方法及其用途
WO2023161291A1 (en) 2022-02-22 2023-08-31 Araris Biotech Ag Peptide linkers comprising two or more payloads

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0934065B1 (en) * 1996-08-30 2006-06-07 University Of Hawaii Novel cryptophycin derivatives as anti-neoplastic agents
US20050175619A1 (en) 2004-02-05 2005-08-11 Robert Duffy Methods of producing antibody conjugates
KR101528939B1 (ko) 2006-07-18 2015-06-15 사노피 암 치료를 위한 ｅｐｈａ2에 대한 길항제 항체
FR2947269B1 (fr) * 2009-06-29 2013-01-18 Sanofi Aventis Nouveaux composes anticancereux
US8953557B2 (en) 2009-06-30 2015-02-10 Alcatel Lucent Roaming method for a mobile terminal in WLAN, related access controller and access point device
AR078470A1 (es) 2009-10-02 2011-11-09 Sanofi Aventis Anticuerpos que se unen especificamente al receptor epha2
CA2934030A1 (en) * 2013-10-15 2015-04-23 Sorrento Therapeutics Inc. Drug-conjugates with a targeting molecule and two different drugs
HUE051389T2 (hu) 2013-10-15 2021-03-01 Seagen Inc Pegilezett gyógyszer-linkerek ligandum-gyógyszer konjugátum javított farmakokinetikájához
WO2015073575A2 (en) * 2013-11-12 2015-05-21 Centre For Probe Development And Commercialization Residualizing linkers and uses thereof
WO2016065142A2 (en) 2014-10-22 2016-04-28 The Johns Hopkins University New scaffolds and multifunctional intermediates for imaging psma and cancer therapy
CN113209306A (zh) * 2014-12-09 2021-08-06 艾伯维公司 具有细胞渗透性的bcl-xl抑制剂的抗体药物缀合物
TW201713363A (zh) * 2015-04-21 2017-04-16 史坦森特瑞斯公司 卡奇黴素構建體及使用方法
TWI714661B (zh) * 2015-11-05 2021-01-01 法商賽諾菲公司 新穎念珠藻素化合物及接合物、其製備與其治療用途
CN108066772B (zh) * 2016-11-14 2021-07-13 中国科学院上海药物研究所 靶向tacstd2的抗体与药物偶联体(adc)分子

Also Published As

Publication number Publication date
WO2018206635A1 (en) 2018-11-15
AU2022204711B2 (en) 2024-01-04
AU2018265333A1 (en) 2019-11-28
TWI778059B (zh) 2022-09-21
MA50764A (fr) 2020-03-18
AU2018265333B2 (en) 2022-07-21
UY37728A (es) 2019-01-02
JP2023085475A (ja) 2023-06-20
US20210228726A1 (en) 2021-07-29
IL270507B1 (en) 2023-04-01
IL270507B2 (en) 2023-08-01
AR111781A1 (es) 2019-08-21
US11007275B2 (en) 2021-05-18
US20200054760A1 (en) 2020-02-20
KR20200005580A (ko) 2020-01-15
EP3621658A1 (en) 2020-03-18
CO2019012108A2 (es) 2020-02-28
ECSP19078277A (es) 2019-11-30
TN2019000303A1 (en) 2021-05-07
CA3062977A1 (en) 2018-11-15
IL270507A (ru) 2019-12-31
AU2018265333C1 (en) 2023-08-17
PH12019550230A1 (en) 2020-07-06
MX2019013421A (es) 2020-02-05
AU2022204711A1 (en) 2022-07-21
US20180369401A1 (en) 2018-12-27
US20200093934A1 (en) 2020-03-26
BR112019023336A2 (pt) 2020-06-16
CN110831633A (zh) 2020-02-21
TW201907957A (zh) 2019-03-01
JP2020519610A (ja) 2020-07-02

Similar Documents

Publication Publication Date Title
EA201992667A1 (ru) Новые пептидные линкеры и конъюгаты на основе криптофицина, их получение и их терапевтическое применение
MX2019009358A (es) Anticuerpo anti-gprc5d y molecula que comprende el anticuerpo.
EA201790359A1 (ru) Пирролобензодиазепины и их конъюгаты, связанные дисульфидной связью с антителами
CY1117563T1 (el) Αντισωματα κατα her3 και χρησεις αυτων
EA201791002A1 (ru) Новые соединения, модулирующие fxr (nr1h4)
EA201991268A2 (ru) Получение конъюгатов "майтансиноид-антитело" одностадийным способом
PE20140247A1 (es) Anticuerpos anti-cd38
MA39193A1 (fr) Modulateurs du gpr6 à base de tétrahydropyridopyrazines
CL2012003054A1 (es) Anticuerpos contra la angiopoyetina 2 humana (ang-2); composicion farmaceutica que contiene dicho anticuerpo; uso del anticuerpo para preparar medicamento destinado a la prevencion de metastasis; acido nucleico que codifica dicho anticuerpo; vector de expresión.
PE20120340A1 (es) Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y melfalan
IN2014CN04961A (ru)
CY1124630T1 (el) Επιλεκτικη αναγωγη αντισωματων τροποποιημενης κυστεϊνης
AR080513A1 (es) Moleculas de union cd37 y sus inmunoconjugados
AR091961A1 (es) Inmunoconjugados y anticuerpos anti-etbr (receptor de endotelina b)
MX2016008189A (es) Conjugados helicoidales-anticuerpo anti-helicoidal unidos covalentemente y usos de los mismos.
AR085155A1 (es) Procesos para preparar compuestos de quinolina y composiciones farmaceuticas que contienen dichos compuestos
CO6270369A2 (es) Nuevos anticuerpos especificos de los peptidos beta -amiloides y sus usos como agentes de diagnostico o drogas
SG178886A1 (en) Humanized anti-cdcp1 antibodies
CY1122441T1 (el) Καινοτομες ενωσεις και συζευγματα κρυπτοφυκινης, η παρασκευη τους και η θεραπευτικη χρηση τους
EA201390467A1 (ru) Композиции антител и способы применения
TR201910573T4 (tr) Staphylococcus aureus'a karşı bağışıklık kazandırmak için stabilize edilmiş proteinler.
EA202092202A1 (ru) Конструкции антител к ror
EA202090014A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
EA201992316A1 (ru) Композиции и способы для диагностики рака предстательной железы
AR077972A1 (es) Anticuerpos contra cdcp1 destinados al tratamiento del cancer